Only one drug is approved to treat persons with mild to moderate Alzheimer's symptoms, despite the fact that the brain protein at the core of this disease, the NMDA receptor, is known to play a central role in several acute and chronic neurodegenerative conditions that impair learning and memory. Gabriela Popescu, Ph.D., assistant professor of biochemistry at the University at Buffalo's School of Medicine and Biomedical Sciences, is hoping to help change that situation.